🇺🇸 FDA
Patent

US 9212191

6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor

granted A61KA61K31/495A61P

Quick answer

US patent 9212191 (6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor) held by GILEAD CONNECTICUT, INC. expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GILEAD CONNECTICUT, INC.
Grant date
Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/495, A61P, A61P11/00, A61P11/02